|In this newsletter we look forward to the EMA Patient Registries Workshop to be held on 28 October 2016 at the EMA offices in London. The workshop is designed to bring together multiple stakeholders including registry owners, industry, HTA representatives and regulators to discuss the challenges and barriers to collaboration and identify specific solutions.|
|“Using registries in real world evidence: Paving the path for success” by Emma Du four and Chris Chinn
On 28 October 2016, the European Medicines Agency (EMA) will hold the EMA registries workshop regarding the use of registries in real world evidence. In advance of this discussion, Emma Du Four, Senior Director Regulatory Policy & Intelligence at AbbVie, and Chris Chinn, Head of Real World Data Strategy and Partnerships at Sanofi, (Co-Chairs of the EFPIA-EBE-VE Real World Evidence-Registries Community), outline the key principles that need to be fulfilled for registries to contribute to the success of real world evidence.
Certain challenges remain in the use of registries, however, both in terms of tapping into the potential of existing registries and establishing new ones. The upcoming October workshop will further the discussion on the use of patient registries as a potential “real world evidence base” and examine some of the hurdles at hand. As we prepare for these conversations, we would like to highlight some of the challenges identified by pharmaceutical companies and regulators in the use of registries, including:
|EFPIA Brussels Office|
Click to view this email in a browser
If you no longer wish to receive these emails, please reply to this message with "Unsubscribe" in the subject line or simply click on the following link: Unsubscribe
107 Leopold III Laan
Read the VerticalResponse marketing policy.